Ans: A. Low molecular weight heparinCurrent guideline-endorsed therapy options for cancer-associated thrombosis include low molecularweight heparin (LMWH), unfractionated heparin (UFH), warfarin & fondaparinux.All current guidelines recommend LMWH for at least 3-6 months in cancer-associated VTE.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.